RxDoctor Payments Data

Diane Rennirt, MD

Internal Medicine · Louisville, KYNPI 1124083969

Payments from drug & device makers

$2,188in general payments, 2019–2025

Across 126 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$666
  • Novo Nordisk$464
  • GSK$160
  • Axsome Therapeutics, Inc.$132
  • Amgen$117
  • Takeda Pharmaceuticals U.S.A., Inc.$85
  • plus $565 from 14 others

What the payments were for

  • Food & beverage$2,16699%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,188 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$26,583
Medicare patients
74
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$47,565
OzempicSemaglutide40$44,937
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$22,755
EliquisApixaban19$20,357
JanuviaSitagliptin Phosphate11$17,329
MounjaroTirzepatide12$12,513
FetzimaLevomilnacipran Hcl17$6,831
MyrbetriqMirabegron11$4,816
Estradiol23$4,756
Breo ElliptaFluticasone/Vilanterol11$4,299
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$3,951
Duloxetine Hcl54$1,756
Azelastine-FluticasoneAzelastine/Fluticasone11$1,590
Rosuvastatin Calcium130$1,568
Metoprolol Succinate52$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$464$44,93740 claims
GSKTrelegy Ellipta, Breo Ellipta$160$27,05427 claims
PfizerEliquis$20$20,35719 claims
MerckJanuvia$38$17,32911 claims
Lilly USA, LLCMounjaro$47$12,51312 claims
AbbVieFetzima$666$6,83117 claims
Astellas Pharma US IncMyrbetriq$14$4,81611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →